Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

G-001

GHB sodium salt solution

1.0 mg/mL in methanol (as salt), ampule of 1 mL, certified reference material, Cerilliant®

Sinónimos:

4-Hydroxybutyric acid sodium salt solution

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C4H7NaO3
Número CAS:
502-85-2
Peso molecular:
126.09
UNSPSC Code:
41116107
NACRES:
NA.24
EC Number:
200-659-6
MDL number:
MFCD00004402
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIA (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland

concentration

1.0 mg/mL in methanol (as salt)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

OCCCC([O-])=O.[Na+]

InChI

1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)/p-1

InChI key

SJZRECIVHVDYJC-UHFFFAOYSA-M

General description

GHB, or γ-hydroxybutyrate, is a central nervous system depressant sold under the brand name Xyrem® and used medically to treat narcolepsy, excessive daytime sleepiness and in rare circumstances, alcoholism. GHB is also used recreationally as an intoxicant and date rape drug. Its many street names include “GBH”, “Liquid X”, “G”, “Juice”, and “Mils”.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Xyrem is a registered trademark of JPI Commercial, LLC

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Clase de almacenamiento

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

John M Roll et al.
Journal of the experimental analysis of behavior, 97(3), 323-331 (2012-06-14)
Gamma-hydroxybutyrate (GHB) is a drug with significant abuse potential. The present study aimed to assess the relative value of escalating doses of GHB to current GHB users via the Multiple Choice Procedure (MCP), and to validate that the dose rated
Jae Seong Lee et al.
Journal of biotechnology, 161(1), 34-41 (2012-06-26)
Previous research showed that co-down-regulation of caspase-3/7 in rCHO cells, unlike Bcl-2 overexpression, did not effectively block apoptotic cell death induced by 3mM sodium butyrate (NaBu). Here, it is found that the control of autophagy is also related to this
Free speech rights outweigh restrictions on promoting drugs off label, court rules.
Bob Roehr
BMJ (Clinical research ed.), 345, e8324-e8324 (2012-12-12)
Ver todos los artículos relacionados